Living EuroGuiDerm Guideline for the systemic treatment of psoriasis vulgaris

 

The general recommendations developed in this guideline are based on the Living Cochrane review (see Methods and Evidence section below). With new evidence and new results becoming available, the guideline development group will consider these and decide if and when an update is necessary. This will also be the case for the recommendations for specific clinical and comorbid situations. 

 

 

Download entire guideline in the most up-to-date version:

Last updated
Updated 2021
Download
Introduction, scoping, population and targeted users
10/2021
We welcome Ivan Bogdanov, Liam Mercieca and Dimitris Rigopoulos to the group.
Disease severity and treatment goals
10/2021
No changes
Methods and evidence section
12/2021
Editorial changes
Main Recommendations and Decision Grid
10/2021
Bimekuzumab was added; guselkumab and PsA was added.
Implementation slides
10/2021
Bimekuzumab was added; guselkumab and PsA was added
IFPA Guideline
10/2021
No changes

Last updated
Updated 2021
Download
Acitretin
10/2021
No changes
Ciclosporin
10/2021
No changes
Fumarates
10/2021
No changes
Methotrexate
10/2021
No changes
Adalimumab
10/2021
No changes
Apremilast
10/2021
No changes
Bimekizumab
10/2021
New chapter
Brodalumab
10/2021
Section on IBD updated
Certolizumab – Pegol
10/2021
No changes
Etanercept
10/2021
No changes
Guselkumab
10/2021
No changes
Infliximab
10/2021
No changes
Ixekizumab
10/2021
No changes
Risankizumab
10/2021
No changes
Secukinumab
10/2021
No changes
Tildrakizumab
10/2021
No changes
Ustekinumab
10/2021
No changes
Biosimilars
10/2021
No changes
Newly approved medications and treatments in the pipeline
10/2021
No changes

Last updated
Updated 2021
Download
Psoriatic arthritis
10/2021
Recommendation concerning guselkumab added
Inflammatory bowel disease
10/2021
Recommendation concerning bimekizumab added
Cancer
10/2021
Editorial changes
Depression
10/2021
No changes
Diabetes Mellitus
10/2021
No changes
Heart disease
10/2021
Recommendation concerning bimekizumab added (same as other IL 17)
Kidney disease
10/2021
No changes
Neurological diseases
10/2021
New data on ixekizumab added
Viral Hepatitis
10/2021
No / update in progress
Tuberculosis: Screening
10/2021
Editorial changes
Tuberculosis: Treatment
10/2021
Editorial changes
Wish for child / Pregnancy
10/2021
Time until pregnancy added for bimekizumab
Vaccionations
10/2021
Information on bimekizumab added
Vaccination against SARS-CoV-2
01/2022
Updated consensus statement
Covid-19
10/2021
No changes
Inmunogenicity
10/2021
No changes

Last updated
Updated 2021
Download
Methods Report
10/2021
No changes
Strength and limitations
10/2021
No changes
References
10/2021
Added new references
Abbreviations
10/2021
No changes